Роль иммуно­гистохимических и молекулярно-генетических маркеров в органосохраняющем лечении начального рака и атипической гиперплазии эндометрия

1. Concin N., Matias-Guiu X., Cibula D., Colombo N., Carien L., Creutzberg C.L. et al. ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol. 2025; 26(8): e423-35. https://dx.doi.org/10.1016/s1470-2045(25)00167-6
2. Каприн А.Д., Старинский В.В., Шахзадова А.О., ред. Состояние онкологической помощи населению России в 2024 году. М.; 2025. 275 с. [Kaprin A.D., Starinsky V.V., Shakhzadova A.O., ed. State of oncological care for the population of Russia in 2024. Moscow; 2025. 275 p. (in Russian)].
3. Colombo N., Creutzberg C., Amant F., Bosse T., González-Martín A., Ledermann J. et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int. J. Gynecol. Cancer. 2016; 26(1): 2-30. https://dx.doi.org/1010.1097/IGC.0000000000000609.
4. Литвинова В.В., Оводенко Д.Л., Двойнишникова А.О., Шебзухова З.Р., Санникова М.В., Шешко П.Л., Пронин С.М., Кирилова Э.В., Назаренко Т.А., Бирюкова А.М., Ашрафян Л.А. Репродуктивные исходы и выживаемость пациенток после органосохраняющего лечения в онкогинекологии: опыт НМИЦ АГП им. В.И. Кулакова. Вопросы онкологии. 2026; 72(2): 386-96. https://dx.doi.org/10.37469/0507-3758-2026-72-2-OF-2506 [Litvinova V.V., Ovodenko D.L., Dvoinishnikova A.O., Shebzukhova Z.R., Sannikova M.V., Sheshko P.L., Pronin S.M., Kirilova E.V., Nazarenko T.A., Biryukova A.M., Ashrafyan L.A. Reproductive outcomes and survival rates in patients after organ preserving treatment in oncogynecology: experience of the V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology. Problems in Oncology. 2026; 72(2): 386-96 (in Russian). https://dx.doi.org/10.37469/0507-3758-2026-72-2-OF-2506].
5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Uterine Neoplasms. Version 3, 2025.
6. Rodolakis A., Scambia G., Planchamp F., Acien M., Di Spiezio Sardo A., Farrugia M. et al. ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Hum. Reprod. Open. 2023; 2023(1): hoac057. https://dx.doi.org/10.1093/hropen/hoac057
7. Contreras N.A., Sabadell J., Verdaguer P., Julià C., Fernández Montoli M.E. et al. Fertility-sparing approaches in atypical endometrial hyperplasia and endometrial cancer patients: current evidence and future directions. Int. J. Mol. Sci. 2022; 23(5): 2531. https://dx.doi.org/10.3390/ijms23052531
8. Sanderson P.A., Critchley H.O., Williams A.R., Arends M.J., Saunders P.T. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum. Reprod. Update. 2017; 23(2): 232-54. https://dx.doi.org/10.1093/humupd/dmw042
9. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Гиперплазия эндометрия. 2025. Доступно по: https://cr.minzdrav.gov.ru/preview-cr/947_1 [Ministry of Health of the Russian Federation. Clinical guidelines. Endometrial hyperplasia. 2025. Available at: https://cr.minzdrav.gov.ru/preview-cr/947_1 (in Russian)].
10. Новикова Е.Г., Пронин С.М., Чулкова О.В. Предрак и начальный рак эндометрия у женщин репродуктивного возраста. М.: МИА; 2005. 132 с. [Novikova E.G., Pronin S.M., Chulkova O.V. Precancer and early-stage endometrial cancer in women of reproductive age. Moscow: MIA; 2005; 132 p. (in Russian)].
11. Galant N., Krawczyk P., Monist M., Obara A., Gajek Ł., Grenda A. et al. Molecular classification of endometrial cancer and its impact on therapy selection. Int. J. Mol. Sci. 2024; 25(11): 5893. https://dx.doi.org/10.3390/ijms25115893
12. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Рак тела матки и саркомы матки. 2024. Доступно по: https://cr.minzdrav.gov.ru/preview-cr/460_4 [Ministry of Health of the Russian Federation. Clinical guidelines. Uterine body cancer and uterine sarcoma. 2024 (in Russian). Available at: https://cr.minzdrav.gov.ru/preview-cr/460_4 (in Russian)].
13. Herrera Cappelletti E., Humann J., Torrejón R., Gambadauro P. Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis. Hum. Reprod. Update. 2022; 28(2): 282-95. https://dx.doi.org/10.1093/humupd/dmab041
14. Huvila J., Pors J., Thompson E.F., Gilks C.B. Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis. Journal of Pathology. 2021; 253(4): 355-65. https://dx.doi.org/10.1002/path.5608
15. Talhouk A., McConechy M.K., Leung S., Li-Chang H.H., Kwon J.S., Melnyk N. et al. A clinically applicable molecular-based classification for endometrial cancers. Br. J. Cancer. 2015; 113(2): 299-310. https://dx.doi.org/10.1038/bjc.2015.190
16. Bosse T., Nout R.A., McAlpine J.N., McConechy M.K., Britton H., Hussein Y.R. et al. Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. Am. J. Surg. Pathol. 2018; 42(5): 561-8. https://dx.doi.org/10.1097/PAS.0000000000001020
17. Wang Y., Lai T., Chu D., Bai J., Yan S., Guo R. The association of molecular classification with fertility-sparing treatment of atypical endometrial hyperplasia and endometrial cancer: a retrospective study. Front. Oncol. 2025; 15: 1506639. https://dx.doi.org/10.3389/fonc.2025
18. Secord A.A., Powell M.A., McAlpine J. Molecular characterization and clinical implications of endometrial cancer. Obstet Gynecol. 2025; 146(5): 660-671. https://dx.doi.org/10.1097/AOG.0000000000006080
19. Karnezis A.N., Leung S., Magrill J., McConechy M.K., Yang W., Chow C. et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. J. Pathol. Clin. Res. 2017; 3(4): 279-93. https://dx.doi.org/10.1002/cjp2.82
20. Raffone A., Travaglino A., Gabrielli O., Micheli M., Zuccalà V., Bitonti G. et al. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer Arch. Gynecol. Obstet. 2021; 303(6): 1393-400. https://dx.doi.org/10.1007/s00404-021-06028-4
21. Britton H., Huang L., Lum A., Leung S., Shum K., Kale M. et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol. Oncol. 2019; 153(3): 487-95. https://dx.doi.org/10.1016/j.ygyno.2019.03.098
22. Maggiore U.L.R., Khamisy-Farah R., Bragazzi N.L., Bogani G., Martinelli F., Lopez S. et al. Fertility-sparing treatment of patients with endometrial cancer: a review of the literature. J. Clin. Med. 2021; 10(20): 4784. https://dx.doi.org/10.3390/jcm10204784
23. Jamieson A., Barroilhet L.M., McAlpine J.N. Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscape. Cancer. 2022; 128(15): 2853-7. https://dx.doi.org/10.1002/cncr.34328
24. Han R., Chen Y., Xu S., Zhang T., Jiang X., Li H. Combined ER/PR co-positivity enhances prognostic stratification within molecular subtypes of endometrial cancer. J. Gynecol. Oncol. 2026; 37(4): e61. https://dx.doi.org/10.3802/jgo.2026.37.e61
25. Raffone A., Travaglino A., Saccone G., Mollo A., De Placido G., Insabato L. et al. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Acta Obstet. Gynecol. Scand. 2019; 98(8): 976-87. https://dx.doi.org/10.1111/aogs.13586
26. Cancer Genome Atlas Research Network; Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., Shen H. et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447): 67-73. https://dx.doi.org/10.1038/nature12113
27. Addante F., d'Amati A., Santoro A., Angelico G., Inzani F., Arciuolo D. et al. Mismatch repair deficiency as a predictive and prognostic biomarker in endometrial cancer: a review on immunohistochemistry staining patterns and clinical implications. Int. J. Mol. Sci. 2024; 25(2): 1056. https://dx.doi.org/10.3390/ijms25021056
28. Протасова А.Э., Раскин Г.А., Собивчак М.С. Микросателлитная нестабильность – надежный маркер сосуществующего эндометриального рака при атипической гиперплазии эндометрия. Опухоли женской репродуктивной системы. 2024; 20(2): 105-12. https://dx.doi.org/10.17650/1994-4098-2024-16-2-105-112 [Protasova А.E., Raskin G.A., Sobivchak M.S. Microsatellite instability as a reliable marker of coexisting endometrial cancer in atypical endometrial hyperplasia. Tumors of Female Reproductive System. 2024; 20(2): 105-12 (in Russian). https://dx.doi.org/10.17650/1994-4098-2024-16-2-105-112].
29. Kloor M., Von Knebel Doeberitz M. The immune biology of microsatellite unstable cancer. Trends Cancer. 2016; 2(3): 121-33.
30. Howitt B.E., Shukla Sh.A., Sholl L.M., Ritterhouse L.L., Watkins J.Ch., Rodig S. et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015; 1(9): 1319-23. https://dx.doi.org/10.1001/jamaoncol.2015.2151
31. Moufarrij S., Gazzo A., Rana S., Selenica P., Abu-Rustum N.R., Ellenso L.H. et al. Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite instability in endometrial cancer: a challenge in molecular classification. Gynecol. Oncol. 2024; 191(1): 1-9. https://dx.doi.org/10.1016/j.ygyno.2024.09.008
32. Ferrari F.A., Uccella S., Franchi M, Scambia G., Fanfani F., Fagotti A. et al. Performance of molecular classification in predicting oncologic outcomes of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Int. J. Gynecol. Cancer. 2025; 35(1): 100016. https://dx.doi.org/10.1016/j.ijgc.2024.100016
33. De Vitis L.A., Schivardi G., Delfrati S., Biffi B., Viscardi A., Rosanu M. et al. The prognostic impact of molecular classification in endometrial cancer that undergoes fertility-sparing treatment. Int. J. Gynecol. Cancer. 2025; 35(1): 100024. https://dx.doi.org/10.1016/j.ijgc.2024.100024
34. Wang Y., Bo L., Fan X., Kang N., Zhang X., Tian L. et al. Molecular classification guides fertility-sparing treatment for endometrial cancer and atypical hyperplasia patients. Curr. Oncol. 2025; 32(6): 317. https://dx.doi.org/10.3390/curroncol32060317
35. Lynch H.T., Snyder C.L., Shaw T.G., Heinen Ch.D., Hitchins M.P. Milestones of Lynch syndrome: 1895-2015. Nat. Rev. Cancer. 2015; 15(3): 181-94. https://dx.doi.org/10.1038/nrc3878
36. Pastor D.M., Schlom J. Immunology of Lynch syndrome. Curr. Oncol. Rep. 2021; 23(8): 96. https://dx.doi.org/10.1007/s11912-021-01085-z
37. Luchini C., Bibeau F., Ligtenberg M.J.L., Singh N., Nottegar A., Bosse T. et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann. Oncol. 2019; 30(8): 1232-43. https://dx.doi.org/10.1093/annonc/mdz116
38. Jamieson A., Thompson E.F., Huvila J., Gilks C.B., Mcalpine J.N. P53abn endometrial cancer: Understanding the most aggressive endometrial cancers in the era of molecular classification. Int. J. Gynecol. Cancer. 2021; 31(6): 907-13. https://dx.doi.org/10.1136/ijgc-2020-002256
39. Раскин Г.А., Каурцева А.С., Мухина М.С. Молекулярная классификация рака эндометрия. Злокачественные опухоли. 2023; 13(3s1): 40-8. https://dx.doi.org/10.18027/2224-5057-2023-13-3s1-40-48 [Raskin G.A., Kautseva A.S., Mukhina M.S. Molecular classification of endometrial cancer. Malignant tumours. 2023; 13(3s1): 40-8 (in Russian). https://dx.doi.org/10.18027/2224-5057-2023-13-3s1-40-48].
40. León-Castillo A. Gilvazquez E., Nout R., Smit V.T., McAlpine J.N., McConechy M. Clinicopathological and molecular characterisation of «multiple-classifier» endometrial carcinomas. J. Pathol. 2020; 250(3): 312-22. https://dx.doi.org/10.1002/path.5373
41. Cosgrove C.M., Tritchler D.L., Cohn D.E., Mutch D.G., Rush C.M., Lankes H.A. et al. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol. Oncol. 2017; 148(1): 174-80. https://dx.doi.org/10.1016/j.ygyno.2017.10.037
42. Leon-Castillo A., de Boer S.M., Powell M.E., Mileshkin L.R., Mackay H.J., Leary A. et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J. Clin. Oncol. 2020; 38(29): 3388-97. https://dx.doi.org/10.1200/JCO.20.00549
43. Pietrus M., Pitynski K., Waligora M., Milian-Ciesielska K., Ludwin A., Socha M.W. et al. Association of membranous WNT-1 and nuclear mTOR with endometrial cancer grade. Int. J. Mol. Sci. 2023; 24(9): 8342. https://dx.doi.org/10.3390/ijms24098342
44. Ravaggi A., Capoferri D., Ardighieri L., Ghini I., Ferrari F., Romani C. et al. Integrated biomarker analysis reveals L1CAM as a potential stratification marker for no specific molecular profile high-risk endometrial carcinoma. Cancers (Basel). 2022; 14(21): 5429. https://dx.doi.org/10.3390/cancers14215429
45. Vermij L., Jobsen J.J., León-Castillo A., Brinkhuis M., Roothaan S., Powell M.E. et al. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry. Br. J. Cancer. 2023; 128(7): 1360-8. https://dx.doi.org/10.1038/s41416-023-02141-0
46. Jamieson A., Huvila J., Chiu D., Thompson E.F., Scott S., Salvador Sh. et al. Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death. Modern Pathology. 2023; 36(4): 100085. https://dx.doi.org/10.1016/j.modpat.2022.100085
47. Stelloo E., Nout R.A., Osse E.M., Jürgenliemk Schulz I.J., Jobsen J.J., Lutgens L.C. et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin. Cancer Res. 2016; 22(16): 4215-24. https://dx.doi.org/10.1158/1078-0432.CCR-15-2878
48. Yin X., Luo B., Li Y. Meta-analysis of the clinicopathologic features of endometrial cancer molecular staging. Front. Oncol. 2025; 14: 1510102. https://dx.doi.org/10.3389/fonc.2024.1510102
49. Stasenko M. Tunnage I., Ashley C.W., Rubinstein M.M., Latham A.J., Da Cruz Paula A. et al. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecol. Oncol. 2020; 156(1): 194-202. https://dx.doi.org/10.1016/j.ygyno.2019.10.028
50. Гаджиева Л.Т., Пронин С.М., Павлович С.В., Кометова В.В., Ашрафян Л.А. Органосохраняющее лечение атипической гиперплазии и начального рака эндометрия в репродуктивном возрасте, исходы лечения. Гинекология. 2023; 25(2): 177-82. https://dx.doi.org/10.26442/20795696.2023.2.202219 [Gadzhieva L.T., Pronin S.M., Pavlovich S.V., Kometova V.V., Ashrafyan L.A. Organ preserving treatment of atypical hyperplasia and early stage endometrial cancer in reproductive age: treatment outcomes. Gynecology. 2023; 25(2): 177-82 (in Russian). https://dx.doi.org/10.26442/20795696.2023.2.202219].
51. Петрожицкая А.А. Танделов Р.К., Зайцев Н.А., Морхов К.Ю. Органосохраняющее лечение атипической гиперплазии и рака эндометрия: современные тенденции. Злокачественные опухоли. 2023; 13(2): 69-79. https://dx.doi.org/10.18027/2224-5057-2023-13-2-5 [Petrozhitskaya A.A., Tandelov R.K., Zaitcev N.A., Morkhov K.Yu. Organ preservation treatment of patients with atypical hyperplasia and endometrial cancer: current trends. Malignant Tumours. 2023; 13(2): 69-79 (in Russian) https://dx.doi.org/10.18027/2224-5057-2023-13-2-5].
52. Кириллова Э.Н., Николаева Т.И., Мыреева С.А., Сосина Т.А. Органосохраняющее лечение при раке эндометрия ранней стадии с реализацией репродуктивной функции. Якутский медицинский журнал. 2023; 2: 131-4. https://dx.doi.org/10.25789/YMJ.2023.82.32 [Kirillova E.N., Nikolaeva T.I., Myreeva S.A., Sosina T.A. Organ-sparing treatment for early-stage endometrial cancer with reproductive function. Yakut Medical Journal. 2023; 2: 131-4 (in Russian). https://dx.doi.org/10.25789/YMJ.2023.82.32].
53. Akhmetzianova A., Raskin G., Esedova A. Molecular diagnosis of endometrial cancer in the Republic of Tatarstan. IJGC. 2025; 35(2S1): 100753. https://dx.doi.org/10.1016/j.ijgc.2024.100753

Поступила 17.07.2026

Принята в печать 01.10.2026